ONCAlert | Upfront Therapy for mRCC

Hematology VIEW MORE >>

In an interview with Targeted Oncology, James L. Ferrara, MD, discussed the prognosis of patients with graft-versus-host-disease and the current treatment strategies. He also highlighted his experience with ruxolitinib and the remaining challenges in this space.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.